Buy & Sell Cytokinetics Inc (CYTK) – Cytokinetics Inc Price Today

Cytokinetics (CYTK) trades at $65.32, down slightly on the day. The stock shows a mixed technical picture with a bearish overall signal but neutral oscillators, trading near its pivot point of $65. Fundamentally, the company is in a high-investment phase with significant losses (-$785M net profit in 2025) as it commercializes its newly FDA-approved heart drug MYQORZO, resulting in negative margins but substantial revenue growth from $88M. Analyst sentiment is overwhelmingly positive with a 94% buy rating and a $89.20 consensus price target, representing ~37% upside.

The investment thesis centers on the successful commercial execution of MYQORZO and upcoming Phase 3 data catalysts in 2026. The primary opportunity is capturing market share in the obstructive hypertrophic cardiomyopathy (oHCM) treatment market. Key risks include intense competition, execution missteps in the drug launch, continued heavy cash burn, and the binary outcome of clinical trials. The company's $1.22B cash position provides runway but the high valuation (P/S of 89.12) demands flawless execution.